Skip to main content
. 2014 Feb 28;6(3):869–891. doi: 10.3390/toxins6030869

Figure 2.

Figure 2

Schematic representation of the major side effects frequency of basiliximab and daclizumab (Ab-CD25), alemtuzumab (Ab-CD52), rituximab (Ab-CD20), eculizumab (Ab-C5), and muromonab-CD3 (OKT3). White dots symbolize infusion-related side effects, black dots infections, gray dots malignancies and white and black striped dots bone marrow complications. As indicated in the box below, dot size is representative of the side effects frequency.